NIH budgets $71M to study rare diseases

The NIH is spending $71 million to launch a host of new studies into rare diseases. Some of those studies will test specific therapies while others will look at the causes of the diseases so that new treatments can be developed. What they discover will be kept by the University of South Florida in Tampa as a way to encourage broader collaboration among the groups studying these ailments.

- read the Wall Street Journal report for more

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.